GALVANI
Financiado
Controlling epileptic brain networks with computationally optimized weak electri...
Epilepsy is a neurological disorder affecting 65 million people worldwide. Pharmacological treatments or surgery are ineffective in one third of the cases – 19 million people. Recent findings indicate that non-invasive brain trans...
Epilepsy is a neurological disorder affecting 65 million people worldwide. Pharmacological treatments or surgery are ineffective in one third of the cases – 19 million people. Recent findings indicate that non-invasive brain transcranial current stimulation (tCS) is safe and of therapeutic promise in epilepsy. However, it is not yet indicated as a standard treatment due to major scientific limitations: unknown mechanisms of action, insufficient account for patient-specific factors, poor understanding of short- and long-term effects.
Our ambition is to transform the care of a large fraction of patients living with drug-resistant epilepsies by solving a fundamental problem: to efficiently target and control large-scale epileptic brain networks with tCS-induced neuromodulatory weak electric fields.
To proceed, GALVANI’s synergetic research strategy addresses four interdisciplinary challenges: (1) Unravel the intricate relationship between weak electric fields and their neurophysiological effects at the level of neurons, neuronal assemblies and networks; (2) Maximize their therapeutic effects by altering the neurodynamics of patient-specific epileptogenic networks; (3) Develop optimal personalized neuromodulation protocols for novel multichannel tCS technologies; (4) Test optimized protocols in a cohort of patients and objectively define potential responders.
The required competences and resources are met in GALVANI, uniting the passion and background of three experts and their teams in biomathematics (computational neuroscience), biophysics (bioelectromagnetism) and medicine (epileptology).
The project vision is that critical features of pathological networks can be effectively captured in a new generation of hybrid computational models developed for tailored therapy. The inflection point is to prevent epileptic seizures from a bottom-up mechanistic understanding and control of tCS effects. This will entail a paradigm shift in epileptic disorders and beyond.
ver más
Duración del proyecto: 72 meses
Fecha Inicio: 2020-05-11
Fecha Fin: 2026-05-31
Fecha Fin: 2026-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2020-05-11
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2019-SyG:
ERC Synergy Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
10M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.68M€ |
Participante